Sucralose, a popular artificial sweetener, has raised health concerns due to its potential negative impacts, including systemic inflammation, metabolic diseases, disruptions in gut microbiota, liver damage, and cellular toxicity. Recent research published in Cancer Discovery indicates that individuals consuming high levels of sucralose, commonly found in diet drinks, may exhibit reduced responses to cancer immunotherapy compared to those with lower or no sucralose intake. The study revealed that sucralose altered gut microbiota, leading to the degradation of arginine, a crucial amino acid needed by immune cells to combat cancer cells.
Sucralose, approved by the FDA as a non-sugar sweetener, is significantly sweeter than sucrose and is widely used in various food and beverage products. Despite its popularity as a sugar substitute, concerns have been raised regarding its health effects and efficacy in weight management. The World Health Organization advised against using non-sugar sweeteners for long-term weight control due to their lack of nutritional value. The recent study’s senior author, Dr. Diwakar Davar, highlighted the significant implications of identifying sucralose as a potential obstacle in cancer immunotherapy and proposed arginine supplementation as a practical solution to enhance treatment outcomes.
The research involved 132 patients with advanced melanoma or non-small cell lung cancer who had undergone immunotherapy or chemoimmunotherapy. Patients consuming high levels of sucralose exhibited poorer responses to immunotherapy and lower survival rates compared to those with lower sucralose intake. These findings emphasize the importance of minimizing non-nutritive sweeteners, particularly sucralose, in the diets of individuals undergoing cancer immunotherapy to optimize treatment outcomes. The study’s lead author, Dr. Abby Overacre, suggested that reducing sucralose intake could be a beneficial strategy for cancer patients on immunotherapy regimens.
Mice models fed sucralose demonstrated resistance to immunotherapy, increased tumor growth, reduced CD8+ T cell infiltration, and higher mortality rates, indicating compromised anti-cancer immune responses. The alterations in gut microbiota induced by sucralose consumption led to the degradation of arginine, a crucial component for T-cell function. Supplementing with arginine or citrulline restored the efficacy of immunotherapy in mice, suggesting a potential intervention for individuals undergoing cancer treatment. The researchers plan to further investigate the impact of other non-nutritive sweeteners on cancer immunotherapy outcomes to enhance patient care.
Key Takeaways:
– High sucralose consumption may hinder cancer immunotherapy responses and decrease survival rates in patients with melanoma or lung cancer.
– Alterations in gut microbiota induced by sucralose can impair T-cell function and compromise the effectiveness of immunotherapy.
– Supplementing with arginine or citrulline could potentially counteract the negative effects of sucralose on cancer immunotherapy outcomes.
– Minimizing non-nutritive sweeteners, particularly sucralose, in the diet of cancer patients undergoing immunotherapy may improve treatment responses.
Tags: immunotherapy
Read more on medicalnewstoday.com